Home

Barbara Klencke

CIK 1647647 · Chief Medical Officer · last filed 2026-07-08

Barbara Klencke is a Chief Medical Officer who has filed 35 SEC Form 4 insider transactions across 6 companies since 2016. The most recent filing, for XNCR, was dated Jul 8, 2026. Across all open-market trades the lifetime net is +$322.0K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $652.8K across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$652.8K

Companies

6

Total Filings

35

Lifetime Open-Market Net

$322.0K

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
XNCR Director 29,974 $19.97 $598.6K $0 4 2026-07-08
TCRX Director 70,000 $0.77 $54.2K $108.0K 8 2026-05-22
ALXO Chief Medical Officer — $1.99 — $0 4 2026-04-17
eFFECTOR Therapeutics, Inc. (EFTRW) Delisted Director — $0.00 — $0 6 2024-06-13
Sierra Oncology, Inc. (SRRA) Delisted Chief Medical Officer 0 $54.99 $0 $214.1K 11 2022-07-01
Sierra Oncology, Inc. (DNAI) Delisted Chief Development Officer — — — $0 2 2016-10-04

Recent Filings

35 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-07-08 XNCR Grant (A) +10,302 $0 EDGAR
2026-05-22 TCRX Grant (A) — $0 EDGAR
2026-04-17 ALXO Grant (A) — $0 EDGAR
2026-03-05 ALXO Grant (A) — $0 EDGAR
2025-09-19 ALXO Grant (A) — $0 EDGAR
2025-07-02 TCRX Grant (A) — $0 EDGAR
2025-06-16 XNCR Grant (A) +13,686 $0 EDGAR
2025-01-23 ALXO Grant (A) — $0 EDGAR
2024-09-24 TCRX Buy (P) +5,000 $26.4K EDGAR
2024-08-27 TCRX Buy (P) +10,000 $56.1K EDGAR
Showing 1–10 of 35
Page 1 of 4
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.